Biotech Gene Therapy Names Juno, Kite, And bluebird bio Still Have Room To Run

Biotech Gene Therapy Names Juno, Kite, And bluebird bio Still Have Room To Run


This report highlights a trio of gene therapy names with additional upside for investors with an 18-month time horizon. BLUE should net at least $150,000 per patient with demand from thousands of patients annually by 2020-2022.



from Biotech News